INDIANAPOLIS, Dec. 16, 2019 /PRNewswire/ -- Eli Lilly and
Company (NYSE: LLY) has announced a global commercialization
agreement to integrate DexCom, Inc. (NASDAQ: DXCM) products into
Lilly's personalized diabetes management system, currently in
development to advance the treatment of diabetes. Under the terms
of the non-exclusive agreement, Lilly will use Dexcom's continuous
glucose monitoring (CGM) devices in both the pen- and pump-based
platforms of the system being designed to help improve diabetes
management.
The agreement with Dexcom builds on Lilly's efforts to provide a
comprehensive system that integrates connected insulin delivery
devices, software and analysis to equip people with type 1 and type
2 diabetes and their healthcare providers with personalized
information and guidance to help simplify management of their
diabetes.
"Even with all of the advances in diabetes technology, insulin
therapy is still overwhelming and complex," said Mike Mason, senior vice president, Connected
Care and Insulins, Lilly Diabetes. "We're excited to include
Dexcom's technology in the solutions we deliver to people with
diabetes to help improve health outcomes by delivering actionable
insights in one connected system. As we integrate our expertise and
insights with those from our partners, like Dexcom, we are aiming
to not only transform the way we develop and deliver medicine, but
to transform how people manage their diabetes."
The personalized diabetes management system being developed will
include both pen- and pump-based platforms. The goal of the
pen-based platform is to integrate personalized data from a
prefilled, disposable insulin pen with data from glucose-sensing
technologies into a compatible software application. Personalized
data is transferred from the pen via an optional attachment. The
goal of the pump-based platform, which is a hybrid-closed loop
system, is to use integrated devices – an insulin pump, continuous
glucose monitor and a dedicated handheld controller or smartphone
application that controls the system – to automate insulin
dosing.
"CGMs provide people with diabetes and their healthcare team
with important real-time data that can help alleviate the burden of
diabetes management, including overall glucose level trends and
information on time spent in target blood glucose range," said
Rick Doubleday, executive vice
president and chief commercial officer of Dexcom. "We're
looking forward to expanding our collaboration with Lilly as we
integrate our technology into their system and believe it will help
reduce some of the complexity that can come from managing diabetes
every day."
About Diabetes
Approximately 30 million
Americans1 and an estimated 425 million adults worldwide
have diabetes.2 Type 2 diabetes is the most common type
internationally, accounting for an estimated 90 to 95 percent of
all diabetes cases in the United
States alone.1 Diabetes is a chronic disease that
occurs when the body does not properly produce or use the hormone
insulin.2
About Lilly Diabetes
Lilly has been a global leader
in diabetes care since 1923, when we introduced the world's first
commercial insulin. Today we are building upon this heritage by
working to meet the diverse needs of people with diabetes and those
who care for them. Through research, collaboration and quality
manufacturing we strive to make life better for people affected by
diabetes. We offer a wide range of therapies and a continued
determination to provide real solutions—from medicines and
technologies to support programs and more. For the latest updates,
visit http://www.lillydiabetes.com/ or follow us on Twitter:
@LillyDiabetes and Facebook: LillyDiabetesUS.
About Eli Lilly and Company
Lilly is a global health
care leader that unites caring with discovery to create medicines
that make life better for people around the world. We were founded
more than a century ago by a man committed to creating high-quality
medicines that meet real needs, and today we remain true to that
mission in all our work. Across the globe, Lilly employees work to
discover and bring life-changing medicines to those who need them,
improve the understanding and management of disease, and give back
to communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us
at lilly.com and lilly.com/newsroom. P-LLY
About Dexcom, Inc.
Dexcom, Inc., headquartered in
San Diego, CA, is dedicated to
helping people better manage their diabetes by developing and
marketing continuous glucose monitoring (CGM) products and tools
for adult and pediatric people with diabetes. With exceptional
performance, comfort and lifestyle flexibility at the heart of its
technology, users have consistently ranked Dexcom highest in
customer satisfaction and loyalty. For more information on the
Dexcom CGM, visit www.dexcom.com.
This press release contains forward-looking statements (as that
term is defined in the Private Securities Litigation Reform Act of
1995) about the potential of the personalized diabetes management
system for the management and treatment of diabetes, and reflects
Lilly's current beliefs. However, as with any pharmaceutical
product or medical device, there are substantial risks and
uncertainties in the process of development and commercialization.
Among other things, there is no guarantee that the connected
diabetes solutions will be commercially successful or that the
company will meet its anticipated timelines for the roll out of
this system. For further discussion of these and other risks and
uncertainties, see Lilly's most recent Form 10-K and Form 10-Q
filings with the United States Securities and Exchange Commission.
Except as required by law, Lilly undertakes no duty to update
forward-looking statements to reflect events after the date of this
release.
1.
|
Centers for Disease
Control and Prevention. National Diabetes Statistics Report, 2017.
Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept
of Health and Human Services; 2017.
|
2.
|
International
Diabetes Federation. IDF Diabetes Atlas, 8th edn. Brussels,
Belgium: International Diabetes Federation, 2017.
http://www.diabetesatlas.org.
|
Refer to:
Maggie Pfeiffer;
monson_maggie@lilly.com; 317-650-5939 (Lilly Diabetes)
Kevin Hern; hern_kevin_r@lilly.com;
317-277-1838 (Lilly Investors)
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lilly-to-integrate-dexcom-cgm-into-personalized-diabetes-management-system-300975004.html
SOURCE Eli Lilly and Company